Literature DB >> 8268341

Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus.

J Torre-Cisneros1, J L Villanueva, J M Kindelan, R Jurado, P Sanchez-Guijo.   

Abstract

We describe two cases of visceral leishmaniasis in patients infected with human immunodeficiency virus (HIV); both cases were resistant to antimony compounds but were cured with liposomal amphotericin B, with no significant toxicity. A review of the previous reported cases of antimony-resistant visceral leishmaniasis in HIV-infected patients confirmed the effectiveness of treatment with liposomal amphotericin B, which directly targets infected macrophages and reaches high levels in plasma and tissue.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8268341     DOI: 10.1093/clinids/17.4.625

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  12 in total

1.  Activity of a new liposomal formulation of amphotericin B against two strains of Leishmania infantum in a murine model.

Authors:  M Paul; R Durand; H Fessi; D Rivollet; R Houin; A Astier; M Deniau
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

2.  Visceral leishmaniasis in a patient with Down syndrome.

Authors:  Claudia Colomba; Laura Saporito; Salvatore Giordano; Laura Infurnari; Patrizia Ajovalasit; Lucina Titone
Journal:  Eur J Pediatr       Date:  2005-11-22       Impact factor: 3.183

3.  AIDS and leishmaniasis.

Authors:  R N Davidson
Journal:  Genitourin Med       Date:  1997-08

4.  Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome.

Authors:  J P Gangneux; A Sulahian; Y J Garin; R Farinotti; F Derouin
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

5.  Sterol methyltransferase is required for optimal mitochondrial function and virulence in Leishmania major.

Authors:  Sumit Mukherjee; Wei Xu; Fong-Fu Hsu; Jigesh Patel; Juyang Huang; Kai Zhang
Journal:  Mol Microbiol       Date:  2018-10-21       Impact factor: 3.501

Review 6.  Leishmania and human immunodeficiency virus coinfection: the first 10 years.

Authors:  J Alvar; C Cañavate; B Gutiérrez-Solar; M Jiménez; F Laguna; R López-Vélez; R Molina; J Moreno
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

7.  Treatment of visceral leishmaniasis.

Authors:  E M Moore; D N Lockwood
Journal:  J Glob Infect Dis       Date:  2010-05

8.  Liposomal amphotericin B and leishmaniasis: dose and response.

Authors:  Shyam Sundar; Jaya Chakravarty
Journal:  J Glob Infect Dis       Date:  2010-05

Review 9.  Human antiprotozoal therapy: past, present, and future.

Authors:  M Khaw; C B Panosian
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

10.  Leishmania infantum: lack of parasite resistance to amphotericin B in a clinically resistant visceral leishmaniasis.

Authors:  R Durand; M Paul; F Pratlong; D Rivollet; M L Dubreuil-Lemaire; R Houin; A Astier; M Deniau
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.